Madrigal Pharma stock soars 10% on profit beat, strong Rezdiffra sales
Madrigal Pharmaceuticals (MDGL) reported Q3 adjusted earnings of $1.83 per share, beating estimates of -$0.83. Revenue reached $431.3M, up 50% YoY. Rezdiffra sales drove growth, with $1.1B in year-to-date sales. Shares rose 10.17% in pre-market trading. The company plans a new Phase 3 trial for MASH cirrhosis.
How this was made
The 30-second read
Why it matters
Earnings beat and 10% stock surge suggest strong short‑term buying pressure.
Market read
The earnings surprise is a primary catalyst for MDGL's price move and may influence biotech peers.
What to watch
Cash burn remains high and upcoming trial results could add volatility.
Background
Madrigal Pharma reported its first profitable quarter, driven by Rezdiffra sales.
Ticker impact
Q3 earnings beat with $1.83 EPS vs -$0.83 estimate and 10% pre‑market price jump.
upward pressure as investors price in higher revenue and profitability.
Earnings beat, profit swing, and 10% pre‑market rally indicate fresh buying interest.
Market effects
Biotech sector may see broader rally on strong rare‑disease drug performance.
U.S. biotech investors likely to benefit; limited immediate impact elsewhere.
Positive earnings could lift global biotech sentiment but effect is modest.
Counterpoint
If the drug pipeline stalls, the current rally may be unsustainable.
Key entities
- companyMadrigal Pharmaceuticals Inc.
Biotech firm developing treatments for rare liver diseases.
